http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
1 online resource (xii, 364 pages) : illustrations
Annotation Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis agents, antitumor vaccines, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents.
Cancer drug discovery and development : new paradigms for a new millennium / E.A. Sausville [and others] -- Evolutionary biosynthesis of anticancer drugs / George R. Pettit -- Some recent developments in the synthesis and structure-activity relationship of novel taxanes / John F. Kadow [and others] -- New generation taxoids and hybrids of microtubule-stabilizing anticancer agents / Iwao Ojima [and others] -- Discodermolide and taxol : a synergistic drug combination in human carcinoma cell lines / Susan Band Horwitz [and others] -- Highly efficient semisynthesis of biologically active epothilone derivatives / Gregory D. Vite [and others] -- Synthetic and semisynthetic analogs of epothilones : chemistry and biological activity / Karl-Heinz Altmann [and others] -- Synthesis and biological activity of epothilones / Ulrich Klar [and others] -- Epothilones and sarcodictyins : from combinatorial libraries to designed analogs / Nicolas Winssinger and K.C. Nicolaou -- Synthesis and structure-activity relationship studies of cryptophycins : a novel class of potent antimitotic antitumor depsipeptides / Chuan Shih [and others] -- Farnesyltransferase inhibitors as potential anticancer agents / J.B. Gibbs [and others] -- Farnesyltransferase inhibitors : from squalene synthase inhibitors to the clinical agent BMS-214662 / John T. Hunt -- Inhibiting farnesyl protein transferase with Sch-66336 : potentially a selective noncytotoxic therapy for human cancer / A.G. Taveras [and others] -- Pyrrolo[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine derivatives as selective inhibitors of the EGF receptor tryosine kinase / G. Caravatti [and others] -- STI571 : a new treatment modality for CML? / Jürg Zimmermann, Pascal Furet, and Elisabeth Buchdunger -- The discovery and development of second-generation matrix metalloproteinase inhibitors for the treatment of cancer / Andy Baxter and John Montana -- Prospects for antiangiogenic therapies based upon VEGF inhibition / Pascal Furet and Paul W. Manley -- Carbohydrate-based tumor antigens as antitumor vaccine agents / Jennifer R. Allen and Samuel J. Danishefsky -- Drugs to enhance the therapeutic potency of anticancer antibodies : antibody-drug conjugates as tumor-activated prodrugs / Walter A. Blättler and Ravi V.J. Chari.
Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann, editor[s].
Title from PDF title page (ACS publications, viewed August 18, 2009).
Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. http://purl.oclc.org/DLF/benchrepro0212 MiAaHDL
digitized 2010 HathiTrust Digital Library committed to preserve pda MiAaHDL
Includes bibliographical references and indexes.
Washington, DC : American Chemical Society, ©2001